[SCHEDULE 13G/A] DarioHealth Corp. SEC Filing

Rhea-AI Filing Summary

Titan Trust 2024 I reports it holds 0 shares of DarioHealth Corp. common stock, representing 0% of the class after disposing of all previously held shares. The filing states the Reporting Person disposed during the three months ended 09/30/2025 of 2,499,618 shares that were issued on 08/14/2025 upon a cashless exercise of a warrant dated 02/15/2024. The filing notes those share figures are shown on a pre-20-to-1 reverse stock split basis implemented on 08/28/2025. The statement affirms the securities were not acquired to influence control of the issuer.

Positive

• Titan Trust 2024 I reports 0% ownership after disposition of previously issued shares
• Disposition completed during the three months ended 09/30/2025, removing that holder’s beneficial stake
• Filing clarifies share counts were pre-20-to-1 reverse split implemented on 08/28/2025

Negative

• None.

Insights

Securities Analyst

Reporting party fully divested; no current ownership or voting power.

The schedule shows Titan Trust 2024 I disposed of all 2,499,618 shares issued on 08/14/2025 via a cashless warrant exercise and now reports 0 beneficial shares (0%). The record is presented on a pre-20-to-1 split basis, clarified by the 08/28/2025 reverse split note.

The chief dependency is the accurate mapping of pre- and post-split share counts when assessing ownership changes; investors should note the timing: disposition occurred within the three months ended 09/30/2025, so any ownership overhang from that issuance has been removed as of this filing.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

DarioHealth Corp.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

23725P209

(CUSIP Number)

09/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 23725P209

1

Names of Reporting Persons

Titan Trust 2024 I

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: Row 5, Row 7 and Row 9 reflect the disposition, during the three months ended September 30, 2025, of 100% of 2,499,618 shares* of common stock of the issuer issued to the Reporting Person on August 14, 2025 upon cashless exercise of a third warrant dated February 15, 2024. *The number of shares represents pre- 20-to1 reverse stock split, which was implemented by the Issuer on August 28, 2025.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: DarioHealth Corp.
(b)	Address of issuer's principal executive offices: 322 W. 57th Street, # 33B, New York, New York, 10019
Item 2.
(a)	Name of person filing: Titan Trust 2024 I
(b)	Address or principal business office or, if none, residence: c/o WhiteHawk Capital Partners LP, as Administrator 11601 Wilshire Blvd., Suite 1980, Los Angeles, CA, 90025
(c)	Citizenship: Titan Trust 2024 I is a Delaware statutory trust organized under the laws of the State of Delaware.
(d)	Title of class of securities: Common Stock, par value $0.0001 per share
(e)	CUSIP No.: 23725P209
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 0
(b)	Percent of class: 0 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Titan Trust 2024 I

Signature:	By: WhiteHawk Capital Partners LP, its Administrator /s/ Robert Louzan
Name/Title:	Robert Louzan/Managing Partner
Date:	10/09/2025

FAQ

What does Titan Trust 2024 I report for DarioHealth (DRIO)?

Titan Trust 2024 I reports it beneficially owns 0 shares, representing 0% of DarioHealth common stock.

When were the disposed shares originally issued to Titan Trust 2024 I?

The shares were issued upon a cashless exercise of a warrant on 08/14/2025 (warrant dated 02/15/2024), totaling 2,499,618 shares pre-reverse split.

Was a reverse stock split involved in the reported figures?

Yes. The filing notes a 20-to-1 reverse stock split implemented on 08/28/2025; the disclosed share count is pre-split.

Over what period did the disposition occur?

The disposition occurred during the three months ended 09/30/2025.

Does the filing state any intent to influence control of the company?

No. The filer certifies the securities were not acquired or held to influence control of the issuer.